Y-mAbs Therapeutics Inc YMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
-
Y-mAbs to Participate in Upcoming Investor Conferences in September
-
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
-
Y-mAbs to Participate in Upcoming Investor Conferences in August
-
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
-
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
-
Y-mAbs Therapeutics New Drug Application Gets FDA Clearance
Trading Information
- Previous Close Price
- $12.95
- Day Range
- $12.84–13.44
- 52-Week Range
- $4.69–20.90
- Bid/Ask
- $13.19 / $13.27
- Market Cap
- $591.89 Mil
- Volume/Avg
- 29,913 / 291,236
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 100
- Website
- https://www.ymabs.com
Comparables
Valuation
|
Metric
|
YMAB
|
NYKD
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.05 | 0.89 | 9.11 |
Price/Sales | 6.55 | 22.47 | 29.11 |
Price/Cash Flow | — | — | 536.38 |
Price/Earnings
YMAB
NYKD
ACLX
Financial Strength
|
Metric
|
YMAB
|
NYKD
|
ACLX
|
|---|---|---|---|
Quick Ratio | 2.67 | 9.28 | 5.85 |
Current Ratio | 2.92 | 9.28 | 6.01 |
Interest Coverage | — | — | −28.35 |
Quick Ratio
YMAB
NYKD
ACLX
Profitability
|
Metric
|
YMAB
|
NYKD
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −10.89% | −17.82% | −1.88% |
Return on Equity (Normalized) | −14.29% | −22.35% | −3.31% |
Return on Invested Capital (Normalized) | −16.96% | −25.52% | −7.10% |
Return on Assets
YMAB
NYKD
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ygwhzmhlt | Brbx | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hhptygwc | Ppxmgf | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nhmrzyn | Qpxdtc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Txjdstp | Hthzcs | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Mcrwfcrbz | Tdt | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Cldnpzn | Nmbl | $28.1 Bil | |||
| Moderna Inc
MRNA
| Zwhtysw | Fdr | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Lwnkfqyc | Wclj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wrwhnwrt | Ptsfwbc | $13.4 Bil | |||
| Incyte Corp
INCY
| Wjsshbgp | Bntyjn | $12.7 Bil |
United States